United Therapeutics Corporation (UTHR)
NASDAQ • Healthcare
Last close at November 18, 2026 at 21:00 UTC
Metrics Over Time
Where the Money Goes
Q3 2026In plain terms: out of every $100 in revenue, United Therapeutics Corporation keeps $31 as net profit.
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
United Therapeutics trailed consensus on EPS but topped expectations on revenue in the third fiscal quarter of 2026, reported November 4, 2026, as revenue rose 4.1% to about $832.5 million (up from roughly $799.5 million a year ago) while EPS of $5.71 came in below the $6.01 estimate (-5%) even as revenue of $832.5 million topped the $781.1 million estimate (+6.6%). Profitability remained high, with gross margin at ~88% and operating margin at ~37%, alongside gross profit of roughly $733 million and operating income of about $307.8 million. Net income fell 23.6% year over year to about $258.6 million (down from roughly $338.7 million), consistent with the year-over-year decline in EPS of -20.3% from $7.16. The company generated operating cash flow of about $306.5 million and repurchased about $500.0 million of stock during the quarter. For the next period, consensus calls for EPS of $6.91 on revenue of $837.8 million.
About United Therapeutics Corporation
United Therapeutics Corporation is a NASDAQ-listed biotechnology company focused on discovering, developing, and bringing to market therapies for chronic and severe illnesses, especially pulmonary hypertension and certain cancers. Its portfolio spans marketed medicines and pipeline programs, and it generated $3.2 billion of revenue in FY2025.
Today's Snapshot
UTHR closed 1.2% below yesterday's close, in line with a weaker sector.
Trading Volume
Below 10d avg (457.6K)
416.3K
vs S&P 500 Today
Underperforming Market
-0.90%
Updated: November 18, 2026 at 21:30 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$534.49 - $585.25Buy
- RSI (14)51.25Neutral
- Stochastic %K (14, 3, 3)45.97Neutral
- MACD Level (12, 26)9.30Neutral
Peers & Related Assets
Get premium market insights delivered directly to your inbox.